Habibian, M., & Dehghani, M. (2018). Out-of-pocket costs analysis of ifosfamide, epirubicin, and etoposide (IEV) and etoposide, solu-medrol-methylprednisolone, high-dose ara-C-cytarabine, and platinol-cisplatin (ESHAP) regimens in the patients with relapsed and refractory lymphoma in Iran. Chronic Diseases Journal, 6(2), 87–92. https://doi.org/10.22122/cdj.v6i2.270